TEVA-ATAZANAVIR 150 MG — DIN 02443791
ATAZANAVIR (ATAZANAVIR SULFATE) : 150 MG · TEVA CANADA LIMITED · CAPSULE · wholesale supply in Canada
Health Canada status: MARKETED
What is TEVA-ATAZANAVIR?
TEVA-ATAZANAVIR 150 MG contains ATAZANAVIR (ATAZANAVIR SULFATE) : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02443791, held by TEVA CANADA LIMITED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Apr-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
How much does Atazanavir cost around the world?
Atazanavir is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Austria | KVP (Kassenverkaufspreis) | 2 | 2 | EUR███.██ |
| South Africa | single exit price | 2 | 2 | ZAR███.██ |
4 pack listings across 4 brand entries and 2 price bases, refreshed 03 Sep 2026. Ranges span every Atazanavir pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Atazanavir in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Atazanavir, across 16 DINs, of which 6 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MYLAN PHARMACEUTICALS ULC | 3 | 3 | MYLAN-ATAZANAVIR | Sourceable in Canada |
| TEVA CANADA LIMITED | 3 | 3 | TEVA-ATAZANAVIR | Sourceable in Canada |
| BRISTOL-MYERS SQUIBB CANADA | 4 | 0 | REYATAZ | No marketed DIN |
| APOTEX INC | 3 | 0 | APO-ATAZANAVIR | No marketed DIN |
| JAMP PHARMA CORPORATION | 3 | 0 | JAMP ATAZANAVIR | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 150 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Atazanavir |
|---|---|
| ATC code | J05AE08 |
| AHFS class | 52:28.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02443791 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2443791 |
| Brand name | TEVA-ATAZANAVIR |
| Generic / active ingredient | ATAZANAVIR (ATAZANAVIR SULFATE) : 150 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | J05AE08 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AE |
| Current status | MARKETED |
| Status date | 18-Apr-2017 |
| Original market date | 2016-02-01 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
6 of 16 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| MYLAN-ATAZANAVIR | 300 MG | CAPSULE | MYLAN PHARMACEUTICALS ULC | MARKETED | 02456893 |
| MYLAN-ATAZANAVIR | 150 MG | CAPSULE | MYLAN PHARMACEUTICALS ULC | MARKETED | 02456877 |
| MYLAN-ATAZANAVIR | 200 MG | CAPSULE | MYLAN PHARMACEUTICALS ULC | MARKETED | 02456885 |
| TEVA-ATAZANAVIR | 200 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | 02443813 |
| TEVA-ATAZANAVIR | 300 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | 02443821 |
| APO-ATAZANAVIR | 150 MG | CAPSULE | APOTEX INC | APPROVED | 02479249 |
| APO-ATAZANAVIR | 300 MG | CAPSULE | APOTEX INC | APPROVED | 02479265 |
| APO-ATAZANAVIR | 200 MG | CAPSULE | APOTEX INC | APPROVED | 02479257 |
| JAMP ATAZANAVIR | 300 MG | CAPSULE | JAMP PHARMA CORPORATION | DORMANT | 02513129 |
| JAMP ATAZANAVIR | 150 MG | CAPSULE | JAMP PHARMA CORPORATION | DORMANT | 02513102 |
2 · Same class — other molecules in ATC J05AE
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Atazanavir | APO-ATAZANAVIR · JAMP ATAZANAVIR · MYLAN-ATAZANAVIR · REYATAZ · +1 more | 16 | 6 | Yes |
| Darunavir | APO-DARUNAVIR · AURO-DARUNAVIR · DARUNAVIR · M-DARUNAVIR · +6 more | 37 | 5 | Yes |
| Ritonavir | AURO-RITONAVIR · NORVIR · NORVIR SEC | 5 | 2 | Yes |
| Nirmatrelvir And Ritonavir | PAXLOVID | 2 | 1 | Yes |
| Amprenavir | AGENERASE | 3 | 0 | Not in Canada |
| Indinavir | CRIXIVAN | 3 | 0 | Not in Canada |
| Nelfinavir | VIRACEPT · VIRACEPT -250MG · VIRACEPT -50MG | 3 | 0 | Not in Canada |
| Saquinavir | FORTOVASE ROCHE · INVIRASE · INVIRASE - CAP 200MG | 3 | 0 | Not in Canada |
| Fosamprenavir | TELZIR | 2 | 0 | Not in Canada |
| Tipranavir | APTIVUS | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AB | Acyclovir · Brincidofovir · Cidofovir · Famciclovir · Ganciclovir · +3 more | 143 | 55 |
| J05AR | Antivirals For Treatment Of Hiv Infections, Combinations · Atanazavir And Cobicistat · Darunavir And Cobicistat · Dolutegravir And Rilpivirine · Emtricitabine And Tenofovir Alafenamide · +16 more | 56 | 39 |
| J05AF | Abacavir · Adefovir Dipivoxil · Didanosine · Emtricitabine · Entecavir · +7 more | 71 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AX | Baloxavir Marboxil · Bulevirtide · Enfuvirtide · Fostemsavir · Inosine Pranobex · +5 more | 19 | 14 |
| J05AG | Delavirdine · Doravirine · Efavirenz · Etravirine · Nevirapine · +1 more | 22 | 10 |
| J05AJ | Cabotegravir · Dolutegravir · Elvitegravir · Raltegravir | 12 | 6 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · +8 more | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What is Atazanavir called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Atazanavir, published to help those searches reach this page.
| Language | Atazanavir |
|---|---|
| Chinese (Simplified) 简体中文 | 阿扎那韦 |
| Russian Русский | Атазанавир |
| Spanish Español | Atazanavir |
| French Français | Atazanavir |
| Portuguese Português | Atazanavir |
| German Deutsch | Atazanavir |
| Turkish Türkçe | Atazanavir |
| Japanese 日本語 | アタザナビル |
| Korean 한국어 | 아타자나비르 |
| Vietnamese Tiếng Việt | Atazanavir |
| Indonesian Bahasa Indonesia | Atazanavir |
| Italian Italiano | Atazanavir |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.